

DELIVERING LONG-TERM SUSTAINABLE VALUE



MUNIR SHAIKH
CHAIRMAN

"To drive better growth, we will continue to incorporate the learnings from our dynamic operating environment and deep industry knowledge of today into tomorrow's business models."

Dear Shareholders,

The start of the new decade has been eventful for everyone.

At Abbott India, our purpose leads us, and we believe that through better health outcomes we will be able to build and sustain a healthier, enriching world. I am happy to inform you that despite volatility and uncertainty, your Company once again delivered a strong performance in FY 2019-20. Through our innovation and agility, we continued to create and deliver long-term sustainable value across the healthcare ecosystem.

Over the last several years, we have continued to adapt to the changing environment. One of our critical success factors has been our agility in adapting to digital transformation that is the norm. Last year, we created several 'first-in-pharma' ecosystems, pioneering initiatives in therapies such as vertigo, liver, thyroid, influenza and others. We have taken a lead in imbibing an innovative culture. We have partnered with health-tech start-ups that endeavour to solve problems in the healthcare space and developed a service plus open ecosystem, a necessity in today's healthcare system. Also, keeping in mind the increasing healthcare needs of our consumers, we have augmented our portfolio and successfully launched 21 new products.


During this challenging time, healthcare companies are relentlessly working alongside the government, to ensure continued manufacturing of medicines with increased efforts on focused research and development, to bring appropriate medical solutions. Your Company is no exception to that, and we have taken extraordinary efforts to remain committed to our customers by ensuring uninterrupted supply of products while keeping the health and safety of our employees a priority. Resilience and adaptability shown by our people during these critical times has been and continues to be, commendable.

I am proud to say that many of our products, patient support programs and differentiated marketing and digital initiatives have received external recognitions. Your Company was also recognized as the Most Innovative MNC of the Year 2019 at the 12th Pharma Leaders Award.

Keeping in mind our 75th year in India and the remarkable performance by the Company, your Board has recommended a final dividend ₹ 107 and special dividend of ₹ 143 per equity share.

Abbott India stands for quality, trust and partnership. We know how to deliver high-quality healthcare, and our heritage is proof that we remain committed for the long-term. As part of our social initiatives, we have enabled access to essential healthcare services and information, with support from qualified healthcare professionals that enhance disease diagnosis.

GROWING DIVIDEND



*includes Special Dividend

₹ 593 Crore
PAT

14.1%
PAT (% OF REVENUE)

The Indian pharmaceutical sector which stands at the cusp of innovation and transformation will be led by the changing healthcare trends. To drive better growth, we will continue to incorporate the learnings from our dynamic operating environment and deep industry knowledge of today into tomorrow's business models. During the year, we laid out our plans to reprioritize resources within key growth areas, streamline operations and redefine our brand strategy.

We are paving the way for greater collaboration amongst our employees and are always open to new ideas to facilitate possible breakthroughs.

As the COVID-19 situation evolves, we will continue to navigate and

provide all necessary support to ensure that products are available for the well-being of our community.

We have had a few changes in our Board this year. Krishna Mohan Sahni retired from the Board at the end of his tenure. Jawed Zia and Mark Murphy also resigned from the Board. We thank them for their valuable contributions. Shalini Kamath was appointed as an Independent Director and we welcome her on the Board.

I would like to recognize Ambati Venu's contributions as Managing Director and congratulate him on his elevation to a senior management position within the Abbott Group effective March 2020. Your Company achieved several milestones under his leadership and are privileged that we will continue to receive his guidance as Non-Executive Director on our Board. I welcome Anil Joseph as Managing Director effective July 1, 2020. Anil has had several years of management experience with Abbott based in Singapore.

On behalf of all Board members, I would like to extend my sincerest gratitude to our employees for their perseverance and commitment, our shareholders for their continued trust in our endeavors and our consumers for their confidence in our products.

Thank you

Munir Shaikh